Compare Inovio Pharmaceuticals Inc (INO) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Occidental Petroleum Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Occidental Petroleum Corporation trades at $55.89 (market cap $54.89B). The key difference: Occidental Petroleum Corporation is far larger — about 614.9× Inovio Pharmaceuticals Inc's market cap, and Occidental Petroleum Corporation pays a 1.88% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | OXY | |
|---|---|---|
Market Cap | $89.27M | $54.89B |
Sector | Health | Energy |
52-Week High | $2.87 | $66.24 |
52-Week Low | $1.05 | $38.92 |
Enterprise Value | $60.28M | $75.98B |
Dividend Yield | — | 1.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Occidental Petroleum (OXY) trades at $55.36, up 0.91% with a bullish technical signal. The company shows strong profitability with 22.42% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights capital spending reductions and Permian Basin growth potential. Analyst consensus is positive with a $65.38 price target representing 18% upside potential from current levels.
OXY presents a compelling investment case with improving debt metrics and consistent earnings outperformance. However, declining revenue trends from $36.6B in 2022 to $21.6B in 2025 and oil price sensitivity remain key risks. The stock's premium valuation (P/E 74.14) requires sustained execution to justify current levels amid volatile energy markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
